Skip to main content
Premium Trial:

Request an Annual Quote

LifeLabs Licenses Transgenomic Technology

NEW YORK (GenomeWeb) – Transgenomic announced today that it has signed an agreement for its ICE-COLD PCR technology with Canadian laboratory services LifeLabs.

Under the terms of the three-year deal, LifeLabs will have a non-exclusive license to the technology and use it in its mutation enrichment platform for cancer testing. The renewable agreement, Transgenomic said, allows LifeLab to benefit from technology improvements and additional product launches during its term.

Additional details of the deal were not disclosed.

"As the largest laboratory service provider in Canada, LifeLabs is committed to offering our customers access to advanced clinical genomic analyses made possible by major new technologies such as ICE-COLD PCR," Joby McKenzie, senior vice president of business development at LifeLabs, said in a statement. "We anticipate that this flexible, versatile mutation enrichment technology will be applied to other molecular testing applications as adoption of genomic and precision medicine expands."

In August, Transgenomic signed a non-exclusive distribution deal for its ICE-COLD PCR-based ICEme mutation enrichment kits with VWR.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.